Lupin gets US FDA nod for Brivaracetam oral solution, launches in US market
Lupin gets US FDA nod for solution'>Brivaracetam oral solution, launches in US market is drawing significant interest across the industry.
Lupin Ltd has received USFDA approval for its Abbreviated New Drug Application (ANDA) for Brivaracetam Oral Solution 10 mg/mL, bioequivalent to UCB, Inc.’s Briviact Oral Solution. The drug is indicated for the treatment of partial-onset seizures in patients aged 1 month and older.
Experts suggest this could influence future trends and innovation in the sector.
More updates are expected as the story develops.
Related Articles
- The $2 Trillion Technological Leap: India's Market Capitalization Boom
- Dalal Street's IPO Party Over? 60% Of Newly Listed Stocks Trade Below Issue Price
- SATTE 2026 To Host Global Tourism Leaders As Industry Aligns Around India’s USD 125 Billion Tourism Market
- Stock Market Today LIVE: Sensex, Nifty 50 likely to begin on a subdued note on February 27; Gift Nifty flat
Source: Original →